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ABSTRACT
Interleukin(IL)-9 is a pleiotropic Th2 type cytokine which has been shown to play an important role in the patho-
genesis of bronchial asthma. This review will concentrate on the structure, the source, and the effects of IL-9 as
well as its induction and inhibition. The signaling of IL-9 through its receptor will be outlined. Moreover the role
of IL-9 in airway hyperresponsiveness, mucus overproduction and airway remodeling in bronchial asthma will
be discussed. Possible treatment options by blocking IL-9 will be outlined．
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INTRODUCTION
Bronchial asthma is a complex inflammatory disorder
of the airways. There are different clinical phenotypes
of asthma in both adults and children. Major clinical
symptoms include a variable degree of airway ob-
struction and airway hyperresponsiveness (AHR) . 1
AHR is characterized as an exaggerated airway re-
sponse to an irritant stimulus, resulting in airway ob-
struction in asthmatics. In asthmatic airways histopa-
thological changes called “remodeling” can be ob-
served. The features of this process include epithelial
changes, subepithelial fibrosis, inflammatory cell infil-
tration, hyperplasia, and hypertrophy of the bronchial
smooth muscle and mucus hypersecretion.2,3 Airway
obstruction in asthma is thought to be secondary to
airway remodeling.
In asthma the airways are infiltrated by activated
inflammatory cells , particularly eosinophils , T lym-
phocytes, and mast cells. At the site of inflammation
these cells release cytokines which have been shown
to play a central role in regulating inflammatory re-
sponses. Bronchial biopsies from asthmatic patients
demonstrate increased expression of IL-4, IL-5, IL-9
and IL-13 when compared to control biopsies . 4-8
Other cytokines such as IL-11, IL-17 and transform-
ing growth factor-β(TGF-β)have been associated with
disease severity and airway remodeling in asthma.9,10
It has been suggested that IL-9 may be responsible
for AHR and mucus overproduction in asthmatics.8,11
More recently, a role for IL-9 in airway repair mecha-
nisms leading to remodeling has been postulated.12
This review will aim at evidence supporting a central
role for IL-9 as an important mediator in asthma. It
will concentrate on the structure of IL-9, its source,
its effects, its receptor(IL-9R)and both the pathologi-
cal and the physiological role of IL-9 will be dis-
cussed. Moreover, the role of IL-9 in AHR, mucus hy-
persecretion and airway remodeling in asthma and
the potential of using IL-9 “blockers” as a possible
treatment in asthma will be reviewed．
STRUCTURE AND GENOMIC ARCHITEC-
TURE OF IL-9
IL-9 belongs to the family of 4-helix bundle cytokines.
This family also includes IL-2, IL-3, IL-4, IL-6, IL-7,
and IL-15. Human IL-9 consists of a 14-kd glycopro-
tein, the mature form of which is composed of 144
amino acids along with a signal sequence of 18 amino
acids. The IL-9 protein contains a high proportion of
cationic amino acid residues and 10 cysteines and has
4 N-linked glycosylation sites．
The human IL-9 gene is located within the Th2 cy-
tokine cluster region 5q31-35. 13,14 This region con-
tains a cytokine gene cluster including IL-4, IL-5, IL-9,
IL-13, and GM-CSF. These mediators have been im-
plicated in allergic inflammation.15,16 The IL-9 gene is
composed of 5 exons and 4 introns over approxi-
mately 4 kb. The 5’ flanking region shows specific
binding sequences for the activator protein 1(AP-1)
and AP-2 transcription factors. A consensus sequence
for IFN-regulating factor 1 was also identified in the 5’
promoter region. The 5’ regulatory region of the IL-9
gene has been shown to contain sequences also seen
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Fig. 1　Immunocytochemistry of IL-9 in alergic airway 
mucosa. Immunoreactive cels in the submucosa stain red. 
Original magnification x400.
in similar regions of the IL-1, IL-2, IL-3, IL-4, IL-5,
IL-6, and GM-CSF genes, suggesting common regula-
tory mechanisms.17 In human T cell leukemia virus
type I-transformed human T cells, C5MJ2, a proximal
region was found to be the minimum sequence for
basal and inducible expression of the IL-9 gene . 19
Within this region a NF-κB site and its adjacent 20-
base pair upstream sequence were demonstrated to
play a critical role for the IL-9 promoter activity. From
those studies it seems that the cooperation of differ-
ent transcription factors such as NF-κB, c-Jun and
others is essential for IL-9 gene expression in T cells．
SOURCES OF IL-9
A variety of cell types including T cells, mast cells,
eosinophils, and neutrophils can produce IL-9. How-
ever, the major cell source of IL-9 is CD4+ T lympho-
cytes.8 Stimulation of human peripheral blood mono-
nuclear cells with anti-CD3 antibodies resulted in
strong expression of IL-9 and could be further en-
hanced by the presence of various T cell mitogens, in-
cluding phorbol myristate acetate.19
Mast cells being an important source of cytokines
in asthmatic airways are another source of IL-9. Mast
cells have been shown to produce both Th1-type and
Th2-type cytokines20-22 and they are also potent pro-
ducers of IL-9.23
Expression of IL-9 mRNA has been detected in hu-
man peripheral blood eosinophils as well as in
eosinophil-differentiated HL-60 cell lines.24 Although
the expression of IL-9 mRNA varied among individual
donors there was a significant difference between the
percentage of IL-9+ eosinophils in asthmatic subjects
compared to normal controls . 24 Eosinophils from
asthmatic subjects also release detectable levels of
IL-9. Moreover , culturing these cells with either
TNFα or IL-1 resulted in increased IL-9 levels in su-
pernatants,24 unlike eosinophils from healthy control
subjects which do not spontaneously release IL-9.24
Furthermore IL-9 mRNA positive eosinophils have
been reported in bronchial biopsy specimens of asth-
matics.8
In asthmatics neutrophils have also been found to
express IL-9.8 However, in that study the percentage
rate of IL-9 mRNA expressing neutrophils was low in-
dicating that neutrophils are not a major cellular
source of IL-9.8
Figure 1 shows immunostaining for IL-9 protein in
the submucosa of allergic airways. Immunoreactive
cells stain red．
INDUCTION AND INHIBITION OF IL-9
Many cytokines are involved in IL-9 gene regula-
tion.19,25 IL-2 can induce IL-9 expression in human T
cells. This effect can be suppressed by anti-IL-2 anti-
bodies19 but can be reversed by adding IL-4 and IL-
10.25 Kinetic analysis of cytokine expression suggests
a cascade of cytokines that are involved in IL-9 ex-
pression. IL-2 is required for IL-4 production, a com-
bination of IL-2 and IL-4 leads to IL-10 production,
and a combination of IL-2, IL-4, and IL-10 is required
for IL-9 induction.25 IL-1, in combination either with
ionomycin or IgE-antigen complexes, induced an ex-
pression of IL-9 protein and mRNA in cultured
murine bone marrow-derived mast cells.23 A marked
increase in IL-9 mRNA and protein expression in
these cells could also be demonstrated after stimula-
tion with kit ligand or IL-10. 26 IL-10 as well as kit
ligand increased promoter activity. IL-4R and anti-IL-
10 neutralizing antibodies could reduce the produc-
tion of IL-9 in murine bone marrow-derived mast
cells.23,26 Therefore regulatory mechanisms for IL-9
generation in mast cells may involve cytokines that
also participate in the regulation of Th2 cells and na-
ive CD4+ T cells. According to these findings the pro-
duction of IL-9 by mast cells may play an important
role in the development of late asthmatic reactions.
IL-9 production can be augmented by IL-1 that can be
detected in airway walls during late asthmatic reac-
tion.27 This effect can be further enhanced by IL-10 or
kit ligand. Both mediators are produced by bronchial
epithelial cells.28,29 Intratracheal injection of kit ligand
has been reported to increase airway hyperreactivity
in allergic and normal mice.30
In atopic asthmatics increased numbers of IL-9
positive cells could be found in allergen challenged
skin.31 Segmental allergen challenge in patients with
atopic asthma increased the numbers of lymphocytes
expressing IL-9 as well as IL-9 protein and IL-9 mRNA
in the bronchoalveolar lavage fluid . 32 These data
show that IL-9 is induced via allergen challenge．
EFFECTS OF IL-9
IL-9 was originally described in the mouse as a potent
T cell and mast cell growth factor.23 IL-9 is a Th2 cy-
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tokine with pleiotropic effects on various cell types. It
enhances the survival of primary mast cells and in-
duces their production of the proinflammatory cy-
tokine IL-6.33,34 IL-9 also stimulates the production of
mast cell proteases and the expression of the high-
affinity IgE receptor(FcεRIα) , suggesting that IL-9
primes mast cells to respond to allergen challenge
through increased cell surface expression of FcεRIα
and the production of proinflammatory mediators
e. g. IL-6 and proteases.35
IL-9 acts as a T cell growth factor in supporting
antigen-independent growth of T helper cell clones.36
IL-9 inhibits lymphokine production by IFN-γ produc-
ing CD4+ T cells and promotes proliferation of CD8+
T cells.37 IL-9 is also able to rescue Th2 type T cell
clones from apoptosis induced by deprivation of
IL-2.38 Selective overexpression of IL-9 in transgenic
mice resulted in T cell infiltration of the airways in
vivo. 39 In IL-9 transgenic mice thymic lymphomas
could be observed. The tumor cells were clonal and
showed double positive expression of CD 4 and
CD8.40
Transgenic mice overexpressing IL-9 were found
to have increased serum levels of all Ig isotypes in-
cluding IgE and an expansion of lymphocytes from
the B1 subset(Mac+ IgM+)could be observed.41,42
Furthermore, accumulation of B cells was detected in
the lungs of IL-9 transgenic mice . IL-9 has been
shown to enhance IL-4 mediated IgE production in
both human and murine B cells.43
Marked eosinophilia has been demonstrated in
transgenic mice overexpressing IL-9 and in naive
mice after intratracheal administration of recombi-
nant IL-9. 39,44 Recently , IL-9 was found to promote
eosinophil maturation in synergy with IL-5.45 IL-9 en-
hances the expression of IL-5Rα on human eosino-
phils.46 In that study, IL-9 inhibited eosinophil apopto-
sis in a dose-dependent manner. Moreover, IL-9 en-
hanced eosinophil development. IL-9 might therefore
induce airway eosinophilia by upregulating the IL-5
response and potentiating the IL-5-mediated matura-
tion of eosinophil precursors.46 Allergen-induced ele-
vated expression of IL-9 in the skin and the lungs of
atopic asthmatics was correlated with increased num-
bers of eosinophils.31,32 These findings further under-
line the role of IL-9 as an important factor in inducing
eosinophilia in allergic inflammation．
Expression of IL-9Rα has been demonstrated in
freshly isolated human peripheral blood polymor-
phonuclear cells (PMN)as well as in BAL-derived
PMN from asthmatic patients.47 IL-9 induces the pro-
duction and release of IL-8 by human neutrophils
from asthmatic subjects. This effect could be blocked
by anti-IL-9 neutralizing antibody.47
Overexpression of IL-9 in transgenic mice resulted
in increased expression of eotaxin , macrophage in-
flammatory protein 1α , and monocyte chemotactic
proteins 1, 3, and 5 in lung epithelial cells.44 Elevated
chemokine expression could also be demonstrated in
cultured primary epithelial cells and in epithelial cell
lines stimulated with IL-9 even in the absence of
IL-4.44 IL-9 was found to stimulate the release of the
T cell chemotactic factors IL-16 and regulated on acti-
vation, normal T cells expressed and secreted(RAN-
TES)from human bronchial epithelial cells.48 Further-
more, IL-9 has been shown to stimulate mucin tran-
scription and upregulate mucus expression in airway
epithelial cells.11,49
Recently it has been demonstrated that IL-9 in-
creased TNFα induced IL-8 release and IL-13 in-
duced eotaxin release from airway smooth muscle
cells . 50 This effect was shown to be mediated via
phosphorylation of ERK.50
According to these data IL-9 has pleiotropic activi-
ties on various cell types that play an important role
in the pathogenesis of asthma. Unlike other cytoki-
nes such as IL-4 or IL-5, IL-9 seems to primarily en-
hance the activities of other cytokines and factors .
This could be important in terms of antagonizing IL-9
activity in the way that inhibiting IL-9 may less likely
compromise normal host defense than the blockage
of other cytokines. Figure 2 summarizes the effects of
IL-9．
IL-9 RECEPTOR
The IL-9 receptor ( IL-9 R ) belongs to the hema-
topoietin receptor superfamily which includes many
other cytokine receptors e. g . IL-2, IL-3, IL-4, IL-5,
IL-7, and IL-10 receptor. The IL-9R is formed by a
ligand specific α subunit(IL-9Rα)and a common γC
chain that is also found in IL-2, IL-4, IL-7, and IL-15 re-
ceptor complexes.51 The human IL-9RA gene is com-
posed of 11 exons and 10 introns ranging approxi-
mately over 17 kb.42 Analysis of the 5’ flanking region
revealed no TATA box. Possible binding sequences
for AP-1, AP-2, AP-3, and nuclear factor κB was dem-
onstrated52 illustrating a potential transcriptional con-
trol of the IL-9RA gene．
The signal transduction of IL-9 is thought to be me-
diated through the Janus kinase-signal transducer
and activator of transcription(STAT)pathway. Consti-
tutive association of Janus kinase 1 with IL-9R was ob-
served.53 IL-9-induced activated complexes contain-
ing STAT-1, STAT-3, and STAT-5 were also found .
This finding was confirmed by the observed presence
of STAT-1 and STAT-3 homodimers and STAT-1
STAT-3 heterodimers after heteromerization of
IL-9 Rα and common γC subunits . 54 Activation of
STAT factors is required in IL-9-induced proliferation
and inhibition of glucocorticoid-induced apoptosis in
T cells.54,55 Recently IL-9 was found to induce tran-
sient phosphorylation of MEK, ERK2 and p90RSK in
murine lymphoid and mast cell lines.56 That study in-
dicated that IL-9 could transiently activate the
mitogen-activated protein kinase pathway and thus
contribute to growth stimulation of hematopoetic cell
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Fig. 2　Efects of IL-9 on inflammatory cels, epithelial cels, and smooth muscle 
cels.
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Fig. 3　Immunocytochemistry of IL-9R in alergic airway 
mucosa. Immunoreactive cels in the epithelium stain red. 
Original magnification x400.
lines.56
Figure 3 shows immunostaining of IL-9R protein in
the epithelium of allergic airway mucosa. Almost all
the epithelial cells express IL-9R(red cells)．
IL-9 AND AIRWAY HYPERRESPONSIVE-
NESS
Airway hyperresponsiveness(AHR)is one of the hall-
mark symptoms of bronchial asthma.1 The chromoso-
mal region 5q31-33 has been identified to contain can-
didate genes for AHR.15 This region contains several
gene candidates for cytokines, growth factors , and
growth factor receptors that may play an important
role in asthmatic inflammation.16 The IL-9 gene has
been localized to this region.13,14
The in vivo importance of IL-9 in the pathophysiol-
ogy of asthma was first determined in animal models
of airway inflammation. Nicolaides et al. have shown
a close association between the IL-9 gene and bron-
chial hyperresponsiveness.14 In that study analysis of
the murine IL-9 gene identified a genetic defect at the
C57BL6(B6)IL-9 locus associated with a lack of IL-9
expression in the lung and reduced AHR in naive B6
mice. In that same study an increased expression of
IL-9 gene and protein in the lung was associated with
AHR in DBAJ2 mice. The tight genotype-phenotype
relation was further supported by the finding that
(B6D2)F1 mice were found to be intermediate in both
lung IL-9 levels and airway responsiveness.14
Selective overexpression of the IL-9 gene in the air-
ways of transgenic mice resulted in massive airway
inflammation, with infiltration of eosinophils and lym-
phocytes , mast cell hyperplasia , and increased
subepithelial collagen deposition.39,44 Moreover, ele-
vated IgE levels, AHR, and increased responsiveness
to antigen stimulation could be observed. In contrast,
overexpression of IL-4 using the CC-10 promoter re-
sulted in baseline eosinophilia without AHR.57
Instillation of recombinant mouse IL-9 into the air-
ways of B6 mice for up to 10 days resulted in time-
dependent and dose-dependent increases in AHR ,
BAL eosinophilia, elevated IgE levels, increased lung
proteases, and submucosal membrane thickening.58
Shimbara et al. investigated the contribution of IL-9
to the pathogenesis of asthma.8 In that study IL-9 and
IL-9R protein and mRNA expression in bronchial tis-
sue from subjects with atopic asthma, sarcoidosis ,
and from atopic and nonatopic healthy control sub-
jects were compared. IL-9 was highly expressed in
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asthmatic airways in comparison to the other disease
groups. In respect to cell type, T cells and, to a lesser
extent , eosinophils and neutrophils were the main
cellular sources of IL-9 production . Furthermore ,
both the degree of airflow obstruction(FEV1)and air-
way responsiveness to metacholine were significantly
correlated with IL-9 mRNA expression. 8 Lamblin et
al. reported that patients with nasal polyposis(NP)as-
sociated with asymptomatic AHR have an eosino-
philic bronchial inflammation similar to that of asth-
matic patients with NP.59 To better evaluate the role
of IL-9 in AHR, bronchial specimens from patients
with NP alone, NP associated with AHR, and NP as-
sociated with asthma were examined. An increased
number of IL-9 mRNA+ cells were detected in sub-
jects with asthma and AHR in comparison to subjects
with NP alone . However , no significant difference
could be demonstrated between subjects with asthma
and subjects with AHR. These data further support
the role of IL-9 in mediating AHR．
IL-9 AND MUCUS HYPERSECRETION
Mucus overproduction is frequently observed in asth-
matics. Several reports have demonstrated upregula-
tion of mucus production by IL-9.11,49 In transgenic
mice constitutive IL-9 expression resulted in elevated
MUC2 and MUC5AC gene expression in airway epi-
thelial cells and PAS-positive staining. Intratracheal
instillation of IL-9 led to similar findings in C57BL6J
mice . 11 IL-9 also induced expression MUC 2 and
MUC5AC in human primary lung cultures and in
the human mucoepidermoid NCI-H292 cell line in vi-
tro.11 These data indicate that IL-9 upregulates mucus
production through induction of mucin gene expres-
sion．
Recently, the mechanism by which IL-9 leads to
mucus over-production has been further elucidated.
Expression of the calcium-activated chloride channel
mCLCA3 in the lungs of a murine model of allergic
asthma was associated with AHR and mucus overpro-
duction.60 Furthermore, introduction of mCLCA3 or
its human counterpart hCLCA1 into the human mu-
coepidermoid cell line NCI-H292 induced mucus pro-
duction as well as MUC5AC expression.60 In IL-9
transgenic mice induction of mCLCA3 has been iden-
tified in the lung epithelium.61 In that study, expres-
sion of mCLCA3 was induced in the lungs of antigen-
exposed mice , and this induction could be sup-
pressed by treatment with IL-9 neutralizing antibod-
ies. The chloride channel hCLCA1 could be induced
in vitro in human primary lung cells by Th2 cytokine
treatment . 61 Our group found an upregulation of
hCLCA1 in mucus producing epithelium of asthmat-
ics compared to control subjects.62 A strong correla-
tion between hCLCA1 mRNA and IL-9 as well as IL-9
R positive cells could be observed. This finding indi-
cates that IL-9 may act through hCLCA1 and that this
channel may be in part responsible for mucus over-
production in bronchial asthmatics.62
IL-9 AND AIRWAY REMODELING
Recent studies have suggested that IL-9 may play an
important role in airway remodeling in asthma. In-
creased expression of IL-9 supports eosinophil infil-
tration and survival.45,46 IL-9 induces the release of T
cell chemoattractant factors from bronchial epithelial
cells48 thus contributing to inflammtion. Further IL-9
has also been shown to induce mucus expression.11,49
In a recent study IL-9 was reported to have little effect
on mucus production in fully differentiated ciliated
human airway epithelia.12 In contrast in the setting of
airway injury repair IL-9 induced goblet cell hyperpla-
sia. This effect could also be observed when epithe-
lium was exposed to IL-9 before it was fully differenti-
ated.12 These findings suggest that increased IL-9 ex-
pression during airway epithelial repair may generate
elevated numbers of goblet cells in asthmatics. Ex-
periments in our own laboratory using the cell lines
showed induction of collagen 1 by stimulation with
IL-9(unpublished observations)．
NEUTRALIZING IL-9 ACTIVITY AS A POTEN-
TIAL TREATMENT
Neutralizing antibodies as well as soluble receptors
have demonstrated involvement of IL-4, IL-5 and
IL-13 in asthmatic responses . 63-65 These strategies
may also offer an opportunity to inhibit selectively
asthmatic inflammation without major side effects as
seen with the use of glucocorticosteroids. However,
by inhibiting these cytokines not only asthmatic in-
flammation is decreased but other important regula-
tory functions of these cytokines are also abolished,
thus affecting the normal host defense system.
Two studies using IL-9 neutralizing antibodies
demonstrated that IL-9 is an important mediator of
asthma.66,67 In one model, exposure of(B6D2)F1 to
either A. fumigatus or dust mite antigen resulted in a
marked allergic inflammatory response including sig-
nificant increases in BAL eosinophils, elevated serum
total IgE levels , increased mucin production , and
AHR in comparison to control or naive animals. Intra-
tracheal administration of IL-9 neutralizing antibodies
reduced AHR, serum total IgE elevations, and led to
increases in BAL eosinophils compared to treatment
with isotype-specific control antibody or untreated
sensitized mice. Alcian BluePAS stains for mucin as
well as overall histopathologic grading confirmed that
the antibody treatment effectively abrogated the aller-
gic response in antigen-challenged animals.66 In the
other study systemic administration of IL-9 neutraliz-
ing attenuated pulmonary eosinophilia and lung dam-
age, the goblet cell hyperplasia, and AHR induced by
antigen challenge with ovalbumin but had no effect
on IL-4, IL-5, and IL-13 mRNA levels in the lungs.67 In
that study(B6D2)F1(moderately hyperresponsive to
bronchoconstrictor challenge)and C57B16J(hypore-
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sponsive to bronchoconstrictor agents )mice were
studied. Interestingly in a mouse model immuniza-
tion with antiIL-9 antibody abrogated mast cell
protease-1 levels as well as eosinophilia after implan-
tation of an IL-9 secreting tumor.68 Moreover, in that
same model antiIL-9 antibody immunization inhibited
Trichuris muris -induced blood eosinophilia . 68 How-
ever , vaccinated mice were not able to expel the
worm. The first IL-9 deficient mice were reported as
being healthy. No abnormalities in development or
phenotype could be observed.69 Naive cytokine pro-
files, Th1 and Th2 cell development, and generation of
naive or antigen-specific antibody responses were
normal.69
Taken together neutralizing IL-9 may offer a prom-
ising approach to the blocking of asthmatic re-
sponses. However, attenuation of IL-9 could possibly
compromise defense against parasites.
ACKNOWLEDGEMENTS
Hans-Peter Hauber is a recipient of a GSKCLA
CIHR fellowship. Qutayba Hamid is a recipient of the
Senior FRSQ Chercheur-Boursier Award．
REFERENCES
1. Busse WW, Lemanske RF Jr. Asthma. New Engl. J. Med.
2001;344:350-362.
2. Redington AE, Howarth PH. Airway remodeling in asthma.
Thorax 1997;52:310-312.
3. Davies DE, Wicks J, Powell RM, Puddicombe SM, Hol-
gate ST. Airway remodeling in asthma : new insights. J.
Allergy Clin. Immunol. 2003;111:215-225.
4. Hamid Q, Azzawi M, Ying S et al. Expression of mRNA
for interleukin-5 in mucosal bronchial biopsies from
asthma. J. Clin. Invest. 1991;87:1541-1546.
5. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-
like bronchoalveolar T-lymphocyte population in atopic
asthma. New Engl. J. Med. 1992;326:298-304.
6. Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Phe-
notype of cells expressing mRNA for TH2-type ( inter-
leukin 4 and interleukin 5)and TH1-type(interleukin 2 and
interferon gamma)cytokines in bronchoalveolar lavage
and bronchial biopsies from atopic asthmatics and normal
control subjects. Am. J. Respir. Cell Mol. Biol. 1995;12:
477-487.
7. Naseer T, Minshall EM, Leung DYM et al. Expression of
IL-12 and IL-13 mRNA in asthma and their modulation in
response to steroid therapy. Am. J. Respir. Crit. Care Med.
1997;155:845-851.
8. Shimbara A, Christodoulopoulos P, Soussi-Gounni A et
al. IL-9 and its receptor in allergic and nonallergic lung
disease : Increased expression in asthma. J. Allergy Clin.
Immunol. 2000;104:108-115.
9. Minshall EM, Leung DYM, Martin RJ et al. Eosinophil-
associated TGF-β1 mRNA expression and airway fibrosis
in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 1997;
17:326-333.
10. Chakir J, Shannon J, Molet S et al. Airway remodeling-
associated mediators in moderate to severe asthma : Ef-
fect of steroids on TGF-β, IL-11, IL-17, and type I and type
III collagen expression. J. Allergy Clin. Immunol. 2003;
111:1293-1298.
11. Louahed J, Toda M, Jen J et al. Interleukin-9 upregulates
mucus expression in the airways. Am. J. Respir. Cell Mol.
Biol. 2000;22:649-656.
12. Vermeer PD, Harson R, Einwalter LA, Moninger T, Zab-
ner J. Interleukin-9 induces goblet cell hyperplasia during
repair of human airway epithelia. Am. J. Respir. Cell Mol.
Biol. 2003;28:286-295.
13. Modi WS, Pollock DD, Mock BA, Banner C, Renauld JC,
Van Snick J. Regional localization of the human glu-
taminase(GLS)and interleukin-9(IL9)gene by in situ hy-
bridization. Cyto. Cell Genet. 1991;57:114-116.
14. Nicolaides NC, Holroyd KJ, Ewart SL et al. Interleukin 9 :
A candidate gene for asthma. Proc. Natl. Acad. Sci. USA
1997;94:13175-13180.
15. Postma DS, Bleecker ER, Amelung PJ et al. Genetic sus-
ceptibility to asthma― bronchial hyperresponsiveness
coinherited with a major gene for atopy. New Engl. J. Med.
1995;333:894-900.
16. Van Leeuwen BH, Martinson ME, Webb GC, Young IG.
Molecular organization of the cytokine gene cluster, in-
volving human IL-3, IL-4, IL-5, and GM-CSF genes, on hu-
man chromosome 5. Blood 1989;31:265-270.
17. Kelleher K, Bean K, Clark SC et al. Human interleukin-9 :
genomic sequence , chromosomal location , and se-
quences essential for its expression in human T-cell leu-
kemia virus(HTLV)-1 transformed human T cells. Blood
1999;77:1436-1441.
18. Zhu YX, Kang LY, Luo W, Li CCH, Yang L, Yang YC. Mul-
tiple transcription factors are required for activation of hu-
man interleukin 9 gene in T cells. J. Biol. Chem. 1996;
271:15815-15822.
19. Houssiau FA, Renauld JC, Fibbe WE, Van Snick J. IL-2 de-
pendence of IL-9 expression in human T lymphocytes. J.
Immunol. 1992;148:3147-3151.
20. Renauld JC, Kermouni A, Vink A, Louahed J, Van Snick J.
Interleukin-9 and its receptor : involvement in mast cell
differentiation and T cell oncogenesis. J. Leukoc. Biol.
1995;57:353-360.
21. Gordon JR, Burd PR, Galli SJ. Mast cells as a source of
multifunctional cytokines. Immunol. Today 1990;11:458-
464.
22. Bradding P. Human mast cell cytokines. Clin. Exp. Allergy
1996;26:13-19.
23. Hultner L, Kolsch S, Stassen M et al. In activated mast
cells , IL-1 up-regulates the production of several Th2-
related cytokines including IL-9. J. Immunol. 2000;164:
5556-5563.
24. Soussi-Gounni A, Nutku E, Koussih L et al. IL-9 expres-
sion by human eosinophils : regulation by IL-1beta and
TNF-alpha. J. Allergy Clin. Immunol. 2000;106:460-466.
25. Houssiau F, Schandene L, Stevens M et al. A cascade of
cytokines is responsible for IL-9 expression in human T
cells. J. Immunol. 1995;154:2624-2630.
26. Stassen M, Arnold M, Hultner L et al. Murine bone
marrow-derived mast cells as potent producers of IL-9 :
costimulatory function of IL-10 and kit ligand in the pres-
ence of IL-1. J. Immunol. 2000;164:5549-5555.
27. Okada S, Inoue H, Yamauchi K et al. Potential role of
interleukin-1 in allergen-induced late asthmatic reactions
in guinea pigs : suppressive effect of interleukin-1 recep-
tor antagonist on late asthmatic reaction. J. Allergy Clin.
76 Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp
Hauber H et al.
Immunol. 1995;95:1236-1245.
28. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hil-
liard JB, Berger M. Normal bronchial epithelial cells con-
stitutively produce the anti-inflammatory cytokine
interleukin-10, which is downregulated in cystic fibrosis.
Am. J. Respir. Cell Mol. Biol. 1995;13:257-261.
29. Wen LP, Fahrni JA, Matsui S, Rosen GD. Airway epithe-
lial cells produce stem cell factor. Biochem. Biophys. Acta
1995;1314:183-186.
30. Campbell E, Hogaboam C, Lincoln P, Lukacs NW. Stem
cell factor-induced airway hyperreactivity in allergic and
normal mice. Am. J. Pathol. 1999;154:1259-1265.
31. Ying S, Meng Q, Kay AB, Robinson DS. Elevated expres-
sion of interleukin-9 mRNA in the bronchial mucosa pf
atopic asthmatics and allergen-induced cutaneous late-
phase reaction : relationships to eosinophils , mast cells
and T lymphocytes. Clin. Exp. Allergy 2002;32:866-871.
32. Erpenbeck VJ, Hohlfeld JM, Volkmann B et al. Segmen-
tal allergen challenge in patients with atopic asthma leads
to increased IL-9 expression in bronchoalveolar lavage
fluid lymphocytes. J. Allergy Clin. Immunol. 2003;111:
1319-1327.
33. Hultner L, Druez C, Moeller J et al. Mast cell growth-
enhancing activity(MEA)is structurally related and func-
tionally identical to the novel mouse T cell growth factor
P40TCGFIII(interleukin 9). Eur. J. Immunol. 1990;20:
1413-1416.
34. Renauld JC, Vink A, Louahed J, Van Snick J. Interleukin-9
is a major anti-apoptotic factor for thymic lymphomas.
Blood 1995;85:1300-1305.
35. Louahed J, Kermouni A, Van Snick J, Renauld JC. IL-9 in-
duces expression of granzymes and high-affinity IgE re-
ceptor in murine T helper clones. J. Immunol. 1995;154:
5061-5070.
36. Van Snick J, Goethals A, Renauld JC et al. Cloning and
characterization of a cDNA for a new mouse T cell growth
factor(P40). J. Exp. Med. 1989;169:363-368.
37. Gessner A, Blum H, Rollinghoff M. Differential regulation
of IL-9 expression after infection with Leishmania major
in susceptible and resistant mice. Immunobiology 1993;
189:419-435.
38. Perdow-Hickman S, Salgame P. Rescue of human T cells
by interleukin-9(IL-9)from IL-2 deprivation-induced apop-
tosis : correlation with alpha subunit expression of the
IL-9 receptor. J. Interf. Cyto. Res. 2000;20:603-608.
39. Temann U, Geba G, Rankin J, Flavell R. Expression of
interleukin-9 in the lungs of transgenic mice causes air-
way inflammation, mast cell hyperplasia , and bronchial
hyperresponsiveness. J. Exp. Med. 1998;188:1307-1320.
40. Renauld JC, Van der Lugt N, Vink A et al. Thymic lym-
phomas in interleukin 9 transgenic mice. Oncogene 1994;
9:1327-1332.
41. McLane MP, Haczku A, van de Rijn M et al. Interleukin-9
promotes allergen-induced eosinophilic inflammation and
airway hyperresponsiveness in transgenic mice. Am. J.
Respir. Cell Mol. Biol. 1998;19:713-720.
42. Vink A, Warnier G, Brombacher F, Renauld JC. Inter-
leukin 9-induced in vivo expansion of the B-1 lymphocyte
population. J. Exp. Med. 1999;189:1413-1423.
43. Dugas B, Renauld JC, Pene J et al. Interleukin-9 potenti-
ates the interleukin-4-induced immunoglobulin(IgG, IgM
and IgE)production by normal human B lymphocytes.
Eur. J. Immunol. 1993;23:1687-1692.
44. Dong Q, Louahed J, Vink A et al. IL-9 induces chemokine
expression in lung epithelial cells and baseline airway
eosinophilia in transgenic mice. Eur. J. Immunol. 1999;
29:2130-2139.
45. Louahed J, Zhou Y, Maloy WL et al. Interleukin 9 pro-
motes influx and local maturation of eosinophils. Blood
2001;97:1035-1042.
46. Soussi Gounni A, Gregory B, Nutku E et al. Interleukin-9
enhances interleukin-5 receptor expression , differentia-
tion and survival of human eosinophils. Blood 2000;96:
2163-2171.
47. Soussi-Gounni A, Koussih L, Nutku E et al. Functional
expression of IL-9 receptor by human neutrophils from
asthmatic donors : role in IL-8 release. J. Immunol. 2001;
166:2768-2774.
48. Little FF, Cruikshank WW, Center DM. IL-9 stimulates
release of chemotactic factors from human bronchial epi-
thelial cells. Am. J. Respir. Cell Mol. Biol. 2001;25:347-
352.
49. Longphre M, Li D, Gallup M et al. Allergen-induced IL-9
directly stimulates mucin transcription in respiratory epi-
thelial cells. J. Clin. Invest. 1999;104:1375-1382.
50. Baraldo S, Faffe DS, Moore PE et al. Interleukin-9 influ-
ences chemokine release in airway smooth muscle : role
of ERK. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003;184:
L1093-1102.
51. Kimura Y, Takeshitak T, Kondo M et al. Sharing of the
IL-2 receptor gamma chain with the functional IL-9 recep-
tor complex. Int. Immunol. 1995;7:115-120.
52. Kermouni A, Van Roost E, Arden KC et al. The IL-9 re-
ceptor gene(IL-9R) : genomic structure, chromosomal lo-
calization in the pseudoautosomal region of the long arm
of the sex chromosomes, and identification of IL-9R pseu-
dogenes at 9gter, 10pter, 16pter, and 18pter. Genomics
1995;29:371-382.
53. Demoulin JB, Uyttenhove C, Van Roost E et al. A single
tyrosine of the interleukin-9(IL-9)receptor is required for
STAT activation, antiapoptotic activity, and growth regula-
tion by IL-9.Mol. Cell. Biol. 1996;16:4710-4716.
54. Bauer JH, Liu KD, You Y, Lai SY, Goldsmith MA. Het-
eromerization of the gamma c chain with the interleukin-9
receptor alpha subunit leads to STAT activation and pre-
vention of apoptosis. J. Biol. Chem. 1999;274:25855-
25861.
55. Demoulin JB, Uyttenhove C, Lejeune D, Mui A, Groner
B, Renauld JC. STAT 5 activation is required for
interleukin-9-dependent growth and transformation of
lymphoid cells. Cancer Res. 2000;60:3971-3977.
56. Demoulin JB, Louahed J, Dumoutier L, Stevens M,
Renauld JC. MAP kinase activation by interleukin-9 in
lymphoid and mast cell lines. Oncogene 2003;22:1763-
1770.
57. Rankin JA, Picarella DE, Gaba GP et al. Phenotypic and
physiologic characterization of transgenic mice express-
ing interleukin 4 in the lung : lymphocytic and eosino-
philic inflammation without airway hyperreactivity. Proc.
Natl. Acad. Sci. USA 1996;93:7821-7825.
58. Levitt RC, McLane MP, MacDonald D et al. IL-9 pathway
in asthma : new therapeutic targets for allergic inflamma-
tory disorders. J. Allergy Clin. Immunol. 1999;103:S485-
491.
59. Lamblin C, Gosset P, Salez F et al. Eosinophilic airway in-
flammation in nasal polyposis. J. Allergy Clin. Immunol.
Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp 77
IL-9 in Asthma
1999;104:85-92.
60. Nakanishi A, Morita S, Iwashita H et al. Role of gob-5 in
mucus overproduction and airway hyperresponsiveness
in asthma. Proc. Natl. Acad. Sci. USA 2001;98:5175-5180.
61. Zhou Y, Dong Q, Louahed J et al. Characterization of a
calcium-activated chloride channel as a shared target of
Th2 cytokine pathways and its potential involvement in
asthma. Am. J. Respir. Cell Mol. Biol. 2001;25:486-491.
62. Toda M, Tulic MK, Levitt RC, Hamid Q. A calcium-
activated chloride channel(HCLCA1)is strongly related to
IL-9 expression and mucus production in bronchial epi-
thelium of patients with asthma. J. Allergy Clin. Immunol.
2002;109:246-250.
63. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13 : a
central mediator of allergic asthma. Science 1998;282:
2258-2261.
64. Grunig G, Warnock M, Wakil AE et al. Requirement for
IL-13 independently of IL-4 in experimental asthma. Sci-
ence 1998;282:2261-2263.
65. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes
J, Foster PS. Integrated signals between IL-13, IL-4, IL-5
regulate airways hyperreactivity. J. Immunol. 2000;165:
108-113.
66. McLane MP, Trepper J, Weiss C et al. Lung delivery of
blocking IL9 antibody inhibits airway hyperresponsive-
ness, BAL eosionphilia, mucin production, serum IgE ele-
vation to natural antigens in a murine model of asthma.
Am. J. Respir. Crit. Care Med. 2000;161:A593.
67. Kung TT, Lou B, Crawley Y et al. Effect of anti-mIL-9 anti-
body on the development of pulmonary inflammation and
airway hyperresponsiveness in allergic mice. Am. J.
Respir. Cell Mol. Biol. 2001;25:600-605.
68. Richard M, Grencis RK, Humphreys NE, Renauld JC, Van
Snick J. Anti-IL-9 vaccination prevents worm expulsion
and blood eosinophilia in Trichuris muris-infected mice.
Proc. Natl. Acad. Sci. USA 2000;97:767-772.
69. Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin
HE, McKenzie AN. IL-9-deficient mice establish funda-
mental roles for IL-9 in pulmonary mastocytosis and gob-
let cell hyperplasia but not T cell development. Immunity
2000;13:573-583.
78 Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp
Hauber H et al.
